KalVista Pharmaceuticals Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing innovative small-molecule protease inhibitors for unmet medical conditions. The company focuses on therapeutic areas such as hereditary angioedema and diabetic macular edema, utilizing its proprietary drug development platform to create targeted treatments. With a strong pipeline of candidates and strategic partnerships, KalVista is well-positioned to make significant contributions to the pharmaceutical industry, striving to enhance patient outcomes through its commitment to scientific advancement.